牛牛AI助理已提取核心訊息
Pfizer Inc's President of R&D, Dolsten Mikael, completed a sale of 21,437 shares of common stock on February 28, 2024. The transaction was executed at a price of $27.04 per share, resulting in a total market value of $579,656.48. Following the sale, Mikael's direct holdings in Pfizer totaled 321,729 shares. Additionally, Mikael holds 1,981 shares indirectly through a Rule 16b-3 Plan. The sale is part of a transaction where securities are delivered or withheld to cover exercise prices or tax liabilities.
Pfizer Inc's President of R&D, Dolsten Mikael, completed a sale of 21,437 shares of common stock on February 28, 2024. The transaction was executed at a price of $27.04 per share, resulting in a total market value of $579,656.48. Following the sale, Mikael's direct holdings in Pfizer totaled 321,729 shares. Additionally, Mikael holds 1,981 shares indirectly through a Rule 16b-3 Plan. The sale is part of a transaction where securities are delivered or withheld to cover exercise prices or tax liabilities.
輝瑞公司研發總裁多爾斯滕·米凱爾於2024年2月28日完成了21,437股普通股的出售。該交易以每股27.04美元的價格執行，總市值爲579,656.48美元。出售後，米凱爾在輝瑞的直接持股總額爲321,729股。此外，米凱爾通過第16b-3條計劃間接持有1,981股股票。出售是交易的一部分，在該交易中，交付或預扣證券以支付行使價或納稅義務。
輝瑞公司研發總裁多爾斯滕·米凱爾於2024年2月28日完成了21,437股普通股的出售。該交易以每股27.04美元的價格執行，總市值爲579,656.48美元。出售後，米凱爾在輝瑞的直接持股總額爲321,729股。此外，米凱爾通過第16b-3條計劃間接持有1,981股股票。出售是交易的一部分，在該交易中，交付或預扣證券以支付行使價或納稅義務。
有用
沒用